Drug Profile
Research programme: IMPDH inhibitors - Bristol-Myers Squibb
Alternative Names: BMS-566419Latest Information Update: 01 Mar 2011
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Acridines; Piperazines
- Mechanism of Action Inosine monophosphate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis; Transplant rejection
Most Recent Events
- 01 Mar 2011 No development reported - Preclinical for Rheumatoid arthritis in USA (PO)
- 01 Mar 2011 No development reported - Preclinical for Transplant rejection in USA (unspecified route)
- 28 Aug 2007 Prelinical data added to the, pharmacokinetics, adverse events and Rheumatic Disease pharmacodynamics sections